« Return to News | Awards & Advancement

EntreMed names two to board of directors

Tuesday, February 7, 2012 01:07 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.

Dr. Wei-Wu He is currently CEO and chairman of OriGene Technologies. He also is the founder and general partner of Emerging Technology Partners, a life sciences focused venture fund. He has also held positions at Human Genome Sciences, Massachusetts General Hospital and Mayo Clinic. He has been involved in founding and funding over 20 biotech companies throughout his career.

Dr. Tak W. Mak is currently the director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a professor in the department of medical biophysics and department of immunology, University of Toronto. He is best known as the leading scientist of the group that first cloned the genes of the human T-cell antigen receptor. Mak has held director and vice president positions at Amgen and Amgen Institute and has experience as a venture capitalist.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.